Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v2-FR | Version v1-EN | |
|---|---|---|
| Language (Changed) | Updated to: French | Was: English |
| Date Updated | 2026-03-05 | 2026-03-05 |
| Drug Identification Number | 02370069 | 02370069 |
| Brand name | BENLYSTA | BENLYSTA |
| Common or Proper name | belimumab lyophilized powder for intravenous infusion | belimumab lyophilized powder for intravenous infusion |
| Company Name | GLAXOSMITHKLINE INC | GLAXOSMITHKLINE INC |
| Ingredients | BELIMUMAB | BELIMUMAB |
| Strength(s) | 400MG | 400MG |
| Dosage form(s) | POWDER FOR SOLUTION | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS | INTRAVENOUS INTRAVENOUS |
| Packaging size | 1x20mL | 1x20mL |
| Additional packaging sizes | ||
| ATC code | L04AG | L04AG |
| ATC description | ||
| Reason for shortage | Demand increase for the drug. | Demand increase for the drug. |
| Anticipated start date | 2026-03-20 | 2026-03-20 |
| Actual start date | ||
| Estimated end date | Unknown | Unknown |
| Actual end date | ||
| Shortage status | Anticipated shortage | Anticipated shortage |
| Tier 3 Status | No | No |
| Company comments | ||
| Health Canada comments |